[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100636156":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":11,"centralContacts":11,"locations":34,"responsibleParty":55,"collaborators":11,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":11,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":11,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":11,"overallStatus":37,"whyStopped":11,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Sinocelltech Ltd.","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"SCTB35 and Lenalidomide","EXPERIMENTAL",null,[13,14],"Drug: SCTB35 injection","Drug: Lenalidomide",{"label":16,"type":17,"description":11,"interventionNames":18},"Rituximab and Lenalidomide","ACTIVE_COMPARATOR",[19,14],"Drug: Rituximab",[21,26,30],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":11},"DRUG","SCTB35 injection","SCTB35 will be subcutaneously administered at a dose as specified",[9],{"type":22,"name":27,"description":28,"armGroupLabels":29,"otherNames":11},"Rituximab","Intravenous Infusion",[16],{"type":22,"name":31,"description":32,"armGroupLabels":33,"otherNames":11},"Lenalidomide","Oral Capsules",[16,9],[35],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Beijing Cancer Hospital","RECRUITING","Beijing","Beijing Municipality","100142","China","CN",{"type":44,"coordinates":45},"Point",[46,47],116.39723,39.9075,{"lat":47,"lon":46},[50],{"name":51,"role":52,"phone":53,"phoneExt":11,"email":54},"Yuqin Song, M.D.","CONTACT","010-88196118","SongYQ_VIP@163.com",{"type":56,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100636156","phase-3-a-study-to-evaluate-the-safety-and-efficacy-of-sctb35-in-combination-with-lenalidomide-in-patients-with-relapsed-or-refractory-follicular-lymphoma-100636156",false,"NCT07562022","A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma","A Phase 3 Randomized, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide Versus Rituximab and Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma","Inclusion Criteria:\n\n* Age 18-80 years old\n* Histologically confirmed Follicular lymphoma (FL) grade 1, 2, or 3a according to WHO 2022 criteria\n* Relapsed or refractory (R\u002FR) disease to at least one prior systemic regimen that contained an anti-CD20 monoclonal antibody (mAb) in combination with chemotherapy\n* Judged by the investigator, the participant must urgently need to receive systemic treatment, based on meeting at least one GELF criterion\n* A measurable or evaluable disease at the time of enrolment\n* ECOG PS 0-2\n* Adequate organ function and bone marrow function\n* Expected survival ≥ 6 months\n\nExclusion Criteria:\n\n* Documented refractoriness to lenalidomide.\n* Have lenalidomide exposure within 12 months prior to randomization","ALL","18 Years","80 Years",{"count":68,"type":69},93,"ESTIMATED","INTERVENTIONAL",[72],"PHASE3","The purpose of this study is to evaluate the efficacy and safety of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular lymphoma (FL).",[75],"Follicular Lymphoma (FL)","2026-08-11",{"date":78,"type":79},"2026-08-13","ACTUAL",{"date":81,"type":79},"2026-06-09",{"date":83,"type":69},"2029-06",{"name":5,"class":6},1]